Hangzhou HighLight Pharmaceutical Co., Ltd. has recently submitted its listing application to the Hong Kong Stock Exchange for the second time, aiming for a main board listing under Chapter 18A rules, with China International Capital Corporation and CMBI acting as joint sponsors.
The company is a clinical-stage biotech firm focused on innovative drugs, with a pipeline of seven small molecule candidates targeting autoimmune and neurodegenerative diseases. Its core product, TLL-018, has advanced to Phase III clinical trials.
However, the company faces numerous challenges for its future development. These include a significant contingent liability of 1.2 billion yuan, an insolvent balance sheet, revenue dependency on a single partner, questionable safety data for its core product, three management changes within six months, and concerns raised by the China Securities Regulatory Commission regarding equity structure and compliance issues.
Mounting Pressure from a $1.2 Billion Bet and Tight Cash Flow
Financially, the company reported zero revenue in 2024 and 107 million yuan in 2025, with corresponding net losses of 226 million yuan and 313 million yuan, representing a 38.1% year-on-year increase in losses. In the first quarter of 2026, revenue returned to zero, with a quarterly net loss of 73.12 million yuan. As of the end of March 2026, the company's accumulated deficit had reached 676 million yuan.
Losses primarily stem from three areas: R&D expenses, which were 127 million yuan in 2024 and 151 million yuan in 2025, increasing with clinical progress; administrative expenses, which were 13.569 million yuan and 33.589 million yuan for the same periods, with the 2025 surge mainly due to share-based payments; and fair value losses on financial instruments issued to investors, a core factor causing significant fluctuations in reported losses.
Regarding revenue sources, the company currently has no approved products on the market. All its income comes from milestone payments from out-licensing collaborations. In 2023, the company recognized an upfront payment of 226 million yuan from a licensing agreement with U.S.-based Biohaven for the TLL-041 project, briefly achieving a profit of 73.79 million yuan that year. In 2024, with no new milestones met, revenue fell to zero. In 2025, 107 million yuan in milestone revenue was recognized as the Biohaven project progressed to Phase IIb/III clinical trials. Revenue returned to zero in the first quarter of 2026. Notably, the company's revenue is almost entirely from a single major client. In 2023, 99% of revenue came from Biohaven, and in 2025, 100% came from the same partner.
In terms of capital structure, due to investor redemption rights attached to multiple past financing rounds, the company must classify preferred shares and other financing instruments as financial liabilities. As of March 31, 2026, the net liability position stood at -909 million yuan, with the carrying value of "financial instruments issued to investors" reaching 1.206 billion yuan.
According to the agreement terms, if the company fails to complete a qualified listing by the end of 2027, investors have the right to demand share redemption at the original investment principal plus an annual interest rate of 8% to 20%. Estimating with a 1.2 billion yuan principal and an average 12% annual interest rate, triggering the redemption clause would require the company to pay over 1.4 billion yuan in principal and interest. As of the end of March 2026, the company's cash and cash equivalents were only about 256 million yuan.
The cash flow situation is equally concerning. In 2024, net cash outflow from operating activities was 119 million yuan, improving to 11 million yuan in 2025, but net outflow was 44 million yuan in the first quarter of 2026. As of Q1 2026, cash and cash equivalents were approximately 256 million yuan. At the current quarterly operational burn rate of about 40 to 50 million yuan, existing cash reserves can only support about 5 to 6 quarters. Considering additional expenses for completing TLL-018's Phase III trials, NDA submission, and commercialization preparation before approval, the cash consumption rate will accelerate further.
Core Product in a Crowded Market with Uncertain Commercial Value
On the business front, the company has built a pipeline of seven assets based on a kinase chemistry platform, covering autoimmune and neurodegenerative diseases. The core product, TLL-018 (Ginoxitinib), is a highly selective dual TYK2/JAK1 inhibitor with best-in-class potential. It is currently undergoing two Phase III registration trials in China for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA).
In April 2026, the company announced that the Phase III trial of TLL-018 for RA met its primary endpoint, showing superiority over the active comparator tofacitinib in ACR50 response rate. An interim analysis for the CSU indication also met its primary endpoint. The company plans to submit an NDA for the RA indication by the end of 2026 and for the CSU indication in the first quarter of 2027.
It is important to note that beating tofacitinib does not guarantee market success. Globally, over ten JAK inhibitors have been approved, covering targets including JAK1, JAK2, and TYK2. In the Chinese market, several products like tofacitinib, baricitinib, upadacitinib, abrocitinib, and ruxolitinib are already approved, with most included in the National Reimbursement Drug List.
In 2025, four products—upadacitinib, tofacitinib, baricitinib, and peficitinib—collectively held 99.6% of the RA JAK inhibitor prescription volume share, with a CR4 approaching 100%, indicating extremely high market concentration. Upadacitinib, with its multi-indication strategy and NRDL access advantages, achieved hospital sales of 590 million yuan in 2025, nearly doubling year-on-year, establishing a solid market barrier.
On pricing, national reimbursement negotiations and volume-based procurement have significantly reduced JAK inhibitor prices. After entering the third round of national procurement, tofacitinib's price dropped by over 90%. Upadacitinib's reimbursement price is about 28.5 yuan per tablet, a 57.1% reduction from its initial launch price. Abrocitinib's reimbursement standard is 32.8 yuan per tablet, a 62.3% cut. Hydrochloride jakotinib is as low as 19.3 yuan per tablet, making it the currently lowest-priced JAK1 inhibitor. As a latecomer, TLL-018 will inevitably face substantial price reduction pressure if it seeks rapid market access through NRDL negotiations. The return on investment for innovative drugs heavily relies on pricing flexibility, and a price war would significantly extend the payback period.
Furthermore, competition in the domestic JAK inhibitor space is intensifying. According to incomplete statistics, there are over 40 JAK inhibitor projects under development in China, with more than five in Phase III clinical trials. Leading domestic pharmaceutical companies like Hengrui Pharmaceuticals, Innovent Biologics, and Kelun Pharmaceutical have their own candidates. Among them, Hengrui's imatinixib was approved in March 2026, becoming the first domestically developed highly selective JAK1 inhibitor, giving it a time-to-market advantage of at least one year over TLL-018. Several other competitors are at different clinical stages, with a wave of domestic JAK inhibitor approvals expected between 2027 and 2028. Even if TLL-018 is launched by then, it will face intense competition in a crowded market, with its potential market share significantly diluted.
Regarding indication selection, while CSU and RA have large patient populations, established treatment options already exist. In RA, there are traditional DMARDs and biologics targeting TNF-α, IL-6, among others, with JAK inhibitors being just one treatment tier. In CSU, antihistamines remain first-line therapy, and biologics like omalizumab are also covered by insurance. TLL-018 needs to demonstrate comprehensive advantages in efficacy, safety, convenience, and price to drive adoption by physicians and patients, a considerable challenge for HighLight Pharma, which lacks commercialization experience.
Beyond TLL-018, the commercialization timelines for the company's other pipelines are even more distant. HL-300 is in Phase Ib/II, HL-400 has just completed Phase I, and TLL-041 (overseas rights licensed to Biohaven), while in global Phase II/III, targets Parkinson's disease—a high-failure-risk area where clinical development risk is much greater than in autoimmune diseases. In the next 3-5 years, the company is likely to have only TLL-018 contributing revenue, highlighting a significant risk of pipeline discontinuity.
While financial and R&D risks are common challenges for innovative drug companies, HighLight Pharma also has underlying concerns in corporate governance and internal controls. In January 2026, the International Cooperation Department of the CSRC issued feedback on the company's overseas listing application, requesting supplementary explanations on five major categories. These cover the pricing basis for all previous capital increases and equity transfers, shareholder background verification, compliance of equity incentive plans, foreign exchange compliance of overseas subsidiaries, and share subdivision arrangements. Notably, it required explanations for "the reasonableness of and reasons for differences in the share purchase prices of shareholders added within the last 12 months" and "whether the implementation of the equity incentive plan is lawful and compliant, and whether there is any benefit transfer," indicating regulatory concerns over the fairness of the company's equity structure.
Furthermore, frequent management changes are noteworthy. In September 2025, just before the first listing application, three directors—Huang Junmin, Pan Xiaogang, and Niu Xinle—resigned simultaneously. In October of the same year, Zhang Yincheng was appointed as a director, and Li Xiang was transferred to an independent non-executive director role. With nearly half the board changing within a short six-month period during the critical IPO window, the reasons behind these moves warrant attention.